NASDAQ · Biotechnology

IMTX (IMTX) Stock

$8.24 -4.52% NASDAQ: IMTX Healthcare

Valuation

MetricValue
Price$8.24
Market Cap$1.10B
P/E Ratio-4.98
P/B Ratio2.24
P/S Ratio29.28
EPS (TTM)$-1.78
52-Week High$12.41
52-Week Low$5.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-43.21%
ROA-22.44%
ROCE-37.60%
Gross Margin100.00%
Operating Margin-5.70%
Net Margin-5.75%
Debt/Equity0.03
Current Ratio11.72

Annual Financials (USD)

Metric20212022202320242025
Revenue$35.0M$173.0M$54.0M$156.0M$48.0M
Operating Profit$-86.0M$30.0M$-102.0M$-39.0M$-182.0M
Net Profit$-95.0M$38.0M$-97.0M$15.0M$-196.0M
EPS$-1.51$0.54$-1.20$0.14$-1.54
Op Margin-248.2%17.3%-188.4%-24.8%-377.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$175.0M$408.0M$510.0M$696.0M$562.0M
Total Liabilities$151.0M$195.0M$285.0M$121.0M$78.0M
Cash$133.0M$149.0M$218.0M$237.0M$346.0M
Borrowings$10.0M$15.0M$15.0M$16.0M$16.0M

Latest News

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting GlobeNewswire · Jun 1, 2026 Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer GlobeNewswire · May 31, 2026 Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting GlobeNewswire · May 30, 2026 Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results Simply Wall St. · May 15, 2026 Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-82.0M$100.0M$18.0M$-158.0M$-170.0M
Investing Cash Flow$2.0M$-216.0M$-62.0M$-169.0M$190.0M
Financing Cash Flow$0$-8.0M$-2.0M$-21.0M$-3.0M
Net Cash Flow$-75.0M$16.0M$70.0M$18.0M$137.0M
Free Cash Flow$-87.0M$94.0M$-13.0M$-175.0M$-176.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-4.14
FCF Yield-17.26%
Quick Ratio8.78
Interest Coverage-182.00
Return 1Y44.03%
Return 3Y-23.79%
Return 5Y-21.56%

Ownership

Insiders Held17.58%
Institutions Held79.47%
Institutions Float Held96.42%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.21,652,1622026-03-31
RTW Investments LP12,869,3402026-03-31
Suvretta Capital Management, LLC11,190,1292026-03-31
Baker Bros. Advisors, LP10,916,6932026-03-31
Perceptive Advisors Llc10,383,4562026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
CVACCureVac N.V. $4.66 +0.00% 5.69 $1.05B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About IMTX

IMTX is led by CEO Harpreet Singh, employs 554 people, headquartered in DE, publicly traded since 2018.

IMTX stock trades at $8.24 with a market capitalization of $1.10B. The stock is valued at a price-to-earnings (P/E) ratio of -4.98, price-to-book of 2.24, price-to-sales of 29.28. Over the past 52 weeks the stock has ranged between $5.05 and $12.41, and currently trades 33.6% below its 52-week high.

On profitability, IMTX generates a return on equity (ROE) of -43.21%, return on capital employed of -37.60%, an operating margin of -5.70%, a net profit margin of -5.75%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides